Recent clinical trials have identified tazemetostat, an EZH2 inhibitor, as promising monotherapy treatment for proximal and distal EPS, with 9 of 62 epithelioid sarcoma patients (∼15%) demonstrating objective response to tazemetostat, although all responders were classified as partial responders. This evidence concerns the gene EZH2 and epithelioid sarcoma.